Overview
Background
A/Prof Mark D. Chatfield is a highly experienced statistician in the UQ Clinical Trials Centre and collaborates with researchers across the Faculty.
In collaboration with health and medical researchers, he has published >200 times in academic journals. He has been an investigator on 30 NHMRC/MRFF funded (>$57M) studies (mostly clinical trials). He has >20 years of experience as a biostatistician in Australia (Brisbane, Darwin, Sydney) and the UK (Cambridge, 2002-2009). He has co-supervised 6 PhD students to completion, and is currently an advisor to 3 PhD students.
He plays an active role in the Australian Clinical Trials Alliance Statistics in Trials Interest Group.
Stata users around the world enjoy using his table1_mc command.
He is an Honorary Fellow (Associate Professor) with Menzies School of Health Research.
Availability
- Mr Mark Chatfield is:
- Not available for supervision
Fields of research
Qualifications
- Bachelor of Arts, University of Oxford
- Masters (Coursework), University of Southampton
- Masters (Coursework), University of Oxford
Research interests
-
Randomised Controlled Trials (RCTs)
Mark has been involved with a plethora of trials of various designs in a broad range of fields. He makes considered, significant contributions to funding applications, trial design, analysis, presentation and interpretation. To date, he has published on 39 randomised trials (protocol and/or results paper). He is involved with methodological research into cluster randomised trials as well as sample size calculations and the anticipated width of 95% confidence intervals.
-
Ready interpretation of log-scale ouput
Ready interpretation of log-scale ouput such as SD(ln Y), Bias(ln estimator). Symmetric percentage differences such as 100(A – B)/0.5(A + B)% or 100(lnA – lnB)%, Bland-Altman plots, and the summarising, modelling and plotting of lognormal data.
-
Meta analysis
Mark has been involved with a variety of meta-analyses. He has found a novel way to interpret the heterogeneity parameter, tau, in random-effects meta-analysis of various ratios (e.g. odds ratio, ratio of means etc). He advocates for the reporting of tau (or exp(tau) for ratio measures) rather than tau^2 as it makes appreciating heterogeneity easier.
Funding
Current funding
Past funding
Supervision
Availability
- Mr Mark Chatfield is:
- Not available for supervision
Supervision history
Current supervision
-
Doctor Philosophy
Gram-negative bloodstream infections in Australian children
Associate Advisor
Other advisors: Dr Geoff Spurling, Professor Colleen Lau, Associate Professor Adam Irwin
-
Doctor Philosophy
Novel trial design in evaluation of antibiotics.
Associate Advisor
Other advisors: Dr Patrick Harris
-
Doctor Philosophy
Treatment Strategies for Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing Enterobacterales
Associate Advisor
Other advisors: Dr Patrick Harris, Dr Brian Forde
Completed supervision
-
2025
Doctor Philosophy
Exploring the use of causal inference in infectious disease epidemiology
Associate Advisor
Other advisors: Professor Tracy Comans, Professor Lisa Hall
-
2024
Doctor Philosophy
Burkholderia pseudomallei: towards rapid diagnosis and management
Associate Advisor
Other advisors: Dr Patrick Harris
-
Media
Enquiries
For media enquiries about Mr Mark Chatfield's areas of expertise, story ideas and help finding experts, contact our Media team: